Imatinib Drug Market

Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.

Imatinib Drug Market contains market size and forecasts of Imatinib Drug in global, including the following market information:

• Global Imatinib Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Imatinib Drug Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Imatinib Drug companies in 2021 (%)

The global Imatinib Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Tablets Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Imatinib Drug include Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc. and Apotex Inc. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Imatinib Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Imatinib Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Imatinib Drug Market Segment Percentages, by Type, 2021 (%)

• Tablets
• Capsules

Global Imatinib Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Imatinib Drug Market Segment Percentages, by Application, 2021 (%)

• Chronic Myelogenous Leukemia
• Gastrointestinal Stromal Tumors
• Others

Global Imatinib Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Imatinib Drug Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Imatinib Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Imatinib Drug revenues share in global market, 2021 (%)
• Key companies Imatinib Drug sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Imatinib Drug sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novartis
• Glenmark Pharmaceuticals Ltd.
• Sun Pharmaceuticals
• Actavis Generics
• Dr. Reddy's Laboratories
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Cipla Inc.
• Apotex Inc.
• Mylan Pharms Inc.